237 results on '"Butera, James"'
Search Results
2. Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease
3. Low microchimeric cell density in tumors suggests alternative antineoplastic mechanism
4. Therapies for Hemorrhagic Transformation in Acute Ischemic Stroke
5. Antigen-Driven Lymphomagenesis
6. Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response‐specific osteo‐mesenchymal profiles
7. Differences in the clinical course of heparin induced thrombocytopenia before and after the availability of HIT IgG class testing
8. Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP
9. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP
10. Lymphopenia and outcomes of bendamustine-based therapy in follicular lymphoma.
11. HIV-Negative Plasmablastic Lymphoma: Not in the Mouth
12. Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study
13. Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response‐specific osteo‐mesenchymal profiles.
14. Acute myelogenous leukemia
15. Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL
16. Antigen-Driven Lymphomagenesis
17. EBV-positive diffuse large B-cell lymphoma of the elderly: A case series from Peru
18. Vincristine Sulfate Liposome Injection (VSLI) with Bendamustine and Rituximab As First-Line Therapy for Indolent B-Cell Lymphomas: A Phase 1 Study
19. Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma
20. Abstract 733: Clonotypic cell-free DNA(cfDNA) in the cerebrospinal fluid (CSF) of patients with aggressive lymphomas
21. Outcomes of bendamustine‐ or cyclophosphamide‐based first‐line chemotherapy in older patients with indolent B‐cell lymphoma
22. Systemic Amyloidosis Mimicking Lung Cancer
23. Complete Remission in Two Cases of Adult T-Cell Leukemia/Lymphoma Treated With Hyper-CVAD: A Case Report and Review of the Literature
24. Synchronous development of acute myeloid leukemia in recipient and donor after allogeneic bone marrow transplantation: report of a case with comments on donor evaluation
25. A multiistitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone
26. Non-Hodgkin’s Lymphoma Involving the Heart: CASE 1. PRIMARY TRANSMURAL CARDIAC LYMPHOMA
27. Unusual Features of Hodgkin’s Disease: CASE 1. HODGKIN’S DISEASE PRESENTING AS A CYSTIC NECK MASS
28. BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
29. Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas
30. Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy
31. Left sided inferior vena cava duplication and venous thromboembolism: case report and review of literature
32. Heterozygous Hemoglobin Sherwood Forest Causing Polycythemia
33. Recipients of Myelotoxic Chemotherapy Have Increased Prevalence of Clonal Hematopoiesis of Indeterminate Potential (CHIP) with a Typical Distribution of Chip-Associated Mutations
34. A new onset of thrombocytopenia and microangiopathic hemolytic anemia in the healthcare setting: A challenge for diagnosis
35. TAFRO Syndrome Associated with EBV and Successful Triple Therapy Treatment: Case Report and Review of the Literature
36. A new onset of thrombocytopenia and microangiopathic hemolytic anemia in the healthcare setting: A challenge for diagnosis.
37. Cryoglobulinemic membranoproliferative glomerulonephritis associated with mucosaassociated lymphoid tissue lymphoma treated with rituximab
38. Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies
39. The Role of Day 14 Bone Marrow Analysis in Determining Leukemia Free Survival and Overall Survival
40. Abstract A14: Cellular immunotherapy for refractory hematological malignancies: Haploidentical donor lymphocyte infusions generate an allogeneic effect that targets leukemia.
41. Cellular immunotherapy for refractory hematological malignancies.
42. The Immunohistochemical Profile and Other Prognostic Factors In Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Treated with R-CHOP 116: 4126
43. Marrow Hypocellularity, but Not Residual Blast Count, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia
44. Recovery Blasts in the Peripheral Blood in AML Patients Who Obtain a Complete Remission Is a Favorable Prognostic Indicator
45. Combination Of Ofatumumab and Bortezomib In Patients With Indolent B-Cell Lymphomas Who Relapsed >6 Months After Rituximab-Containing Regimen: A Brown University Oncology Research Group Phase II Study
46. Grey Zone Lymphoma, Unclassifiable With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma: Better Results With CHOP-Like Regimens
47. Cellular immunotherapy for refractory hematological malignancies
48. Spontaneous regression of chronic lymphocytic leukemia to a monoclonal B-lymphocytosis or to a normal phenotype
49. Incidence of Direct Thrombin Inhibitor Therapy for Presumed Heparin Induced Thrombocytopenia Before and After Implementation of Heparin Induced Thrombocytopenia IgG Subtype Antibody Test
50. Spontaneous Remission of Chronic Lymphocytic Leukemia, Possibly More Rare Then Previously Reported?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.